NCT03426553View on ClinicalTrials.gov

Clinical Use of Pathogen Reduced Red Blood Cell Suspension

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

September 17, 2018

Study Completion Date

December 17, 2018

Conditions
Oncologic DisordersHematologic Diseases
Interventions
BIOLOGICAL

Riboflavin+UV RBC

35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology

BIOLOGICAL

irradiated RBC

35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension

Trial Locations (1)

117997

Federal Research Center for pediatric hematology, oncology and immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT03426553 - Clinical Use of Pathogen Reduced Red Blood Cell Suspension | Biotech Hunter | Biotech Hunter